Coherus Oncology, Inc. Net Fee Amt
Coherus Oncology, Inc. (CHRS) had Net Fee Amt of $1.53 thousand as of 2026-08-03, per its S-8 filed 2026-08-05.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-05
- 2026-08-03: Net Fee Amt $1.53K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-03 | $1.53K S-8 · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |